Janux Therapeutics (JANX) Receivables - Other (2023 - 2026)

Janux Therapeutics (JANX) has 4 years of Receivables - Other data on file, last reported at $7.5 million in Q1 2026.

• On a quarterly basis, Receivables - Other rose 33.63% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 33.63% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, up 19.46% from the prior year.
• Receivables - Other for Q1 2026 stood at $7.5 million, up from $6.4 million in the prior quarter.
• Over the last five years, Receivables - Other for JANX reached as high as $7.5 million in Q1 2026 and fell as low as $2.2 million in Q4 2023.
• Historically, Receivables - Other has averaged $5.2 million across 4 years, with a median of $5.5 million in 2024.
• Across the five-year window, Receivables - Other soared 149.01% in 2024 and increased 19.46% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $2.2 million in 2023, then surged by 149.01% to $5.4 million in 2024, then increased by 19.46% to $6.4 million in 2025, then rose by 16.1% to $7.5 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $7.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.3 million in Q3 2025.